🛡️ Just a quick check We’re checking your connection to prevent automated abuse
Read moreDetailsYou don't have permission to access "http://www.medpagetoday.com/meetingcoverage/esc/122820" on this server. Reference #18.8bc1c917.1792254640.15b9738d https://errors.edgesuite.net/18.8bc1c917.1792254640.15b9738d
Read moreDetailsMUNICH — Switching from a 3-hour to a 1-hour high-sensitivity cardiac troponin pathway for patients with suspected myocardial infarction (MI)...
Read moreDetailsMUNICH — Adding the investigational factor XIa inhibitor milvexian to standard antiplatelet therapy did not reduce cardiovascular (CV) events after...
Read moreDetails🛡️ Just a quick check We’re checking your connection to prevent automated abuse
Read moreDetailsMUNICH — Atorvastatin reduced the risk of major cardiovascular (CV) events, predominantly nonfatal events, by 30% compared with placebo in...
Read moreDetailsYou don't have permission to access "http://www.medpagetoday.com/opinion/second-opinions/122801" on this server. Reference #18.8bc1c917.1792247446.1504c856 https://errors.edgesuite.net/18.8bc1c917.1792247446.1504c856
Read moreDetails🛡️ Just a quick check We’re checking your connection to prevent automated abuse
Read moreDetailsYou don't have permission to access "http://www.medpagetoday.com/meetingcoverage/esc/122822" on this server. Reference #18.94c1c917.1792240235.1a71f1f8 https://errors.edgesuite.net/18.94c1c917.1792240235.1a71f1f8
Read moreDetails🛡️ Just a quick check We’re checking your connection to prevent automated abuse
Read moreDetails